2024-fevral: Several new drugs and promising therapies, such as chimeric antigen receptor T-cell therapy, have ushered in a “renaissance” for lupus, according to a speaker at the symposium Basic and Clinical Immunology for the Busy Clinician.
Klivlend klinikasidan Emili Littljonning so'zlariga ko'ra, monoklonal antikorlar va interferonlar 2020 yildan beri paydo bo'lgan tizimli qizil yuguruk uchun ikkita qo'shimcha potentsial davolash usuli hisoblanadi.
“2020 is what many of us consider the lupus renaissance,” Littlejohn told attendees during the hybrid meeting. “This is a time where, finally, we had many drugs entering the armamentarium very quickly.”
Siz o'qishni xohlashingiz mumkin: CAR T Xitoyda hujayra terapiyasi
According to Littlejohn, there have been a lot of exciting new treatments for SLE since the quick approvals of belimumab (Benlysta, GSK), voclosporin (Lupkynis, Aurinia), and anifrolumab (Saphnelo, AstraZeneca). CAR T-cell therapy might be the most exciting of these.
“This is used in the oncology world—we have seen it in [B-cell acute lymphoblastic leukemia], [B-cell non-Hodgkin’s lymphoma] and mantel cell lymphoma,” Littlejohn said. “The question is: What about in our diseases?”
Littljonning ta'kidlashicha, ko'p a'zolar bilan kasallangan besh bemorni qamrab olgan nemis tadqiqotida qatnashgan barcha bemorlar nefritni to'xtatadigan holatga erisha oldilar. Littlejonning qo'shimcha qilishicha, natijalar umid beradi, ammo terapiya xavf-xatarsiz emas.
Siz o'qishni xohlashingiz mumkin: CAR T Xitoyda ko'p miyelom uchun hujayra terapiyasi
"Sitokinlarni chiqarish sindromi xavfi katta, ayniqsa ICANS - bu juda qo'rqinchli", dedi u.
"Menimcha, bu beshta bemorni [CAR-T hujayra terapiyasi bilan davolangan] va ular qanchalik yaxshi ishlaganini hisobga olsak, bu sohada juda ko'p va'dalar bor", deya qo'shimcha qildi u.
Shu bilan bir qatorda CAR T-hujayra terapiyasi are in development. These include litifilimab (BIIB059, Biogen), interferon—kinoid, obinutuzumab (Gazyva, Genentech) and iberdomide (Bristol Myers Squibb).
Interferon-kinoid muhim sinovlarda so'nggi nuqtalarga javob bera olmadi va uning kelajagi "noaniq", dedi Littlejon.
Siz o'qishni xohlashingiz mumkin: Xitoyda CAR T Cell terapiyasi narxi
"Litifilimab dastlab teri qizil yugurukli bemorlarda o'rganilgan, jami 132 kishi", dedi Littlejon. "Ular aniqlagan narsa shundaki, u 16-haftada terining CLASI ballining pasayishi bilan asosiy yakuniy nuqtalarga javob berdi."
Bundan tashqari, Littlejonning so'zlariga ko'ra, preparat faol kasallikdagi bo'g'imlar sonini kamaytirishda muvaffaqiyat qozongan.
Nihoyat, obinutuzumab qizil yugurukli nefritli bemorlarda o'zining asosiy yakuniy nuqtasiga erishdi, dedi Littlejon.
